Embla Medical Hf · OMXCOP:EMBLA
Embla Medical Hf — Q1 2025 Earnings Presentation
12 slides from Embla Medical Hf's earnings presentation, Apr 29, 2025
Slide 1: Q1 2025 Conference Call
A leading global provider of innovative mobility solutions Q1 2025 Conference Call Sveinn Sölvason, President and CEO G. Arna Sveinsdottir, CFO April 29, 2025 0
Slide 2: Key Highlights for Q1 2025
Key Highlights for Q1 2025 Q1 Performance Operations Guidance/SBB Local currency R&D progress 2025 Guidance reiterated growth ✓ André Rocha appointed as new • 5-8% Organic sales growth EVP R&D at Embla Medical +4% • 20-21% EBITDA margin ✓ NAVii® and Icon® advance into full launch following encouragi
Slide 3: Strong EMEA and APAC growth in Prosthetics & Neuro Orthotics, while Americas ended down
Strong EMEA and APAC growth in Prosthetics & Neuro Orthotics, while Americas ended down; mainly due to a decline in Patient Care APAC APAC Q1: +13% 19 Americas Q1: -1% 18 13% 150 7% 17 9% USDm 100 16 6% 15 USDm 2% 14 3% 50 1% 0% 13 0% -1% Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 0 Sales (USD) Q1'24 Q2'24 Q3'24
Slide 4: Prosthetics & Neuro Orthotics sales
Prosthetics & Neuro Orthotics sales % of total sales in Q1 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Continued strong performance in EMEA across key markets, supported by recently launched 51% innovation (Navii / Pro-Flex Terra) 111 9% ▪ Americas: Modest performance in Americas follo
Slide 5: Bracing & Supports sales
Bracing & Supports sales % of total sales in Q1 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Pockets of growth in key markets but offset by decline in other countries 35 0% ▪ Americas: Good start to the year, somewhat offset USD million organic growth by slower growth towards the end of
Slide 6: Patient Care sales
Patient Care sales % of total sales in Q1 Year-to-date sales Year-to-date growth Highlights ▪ EMEA: Solid growth in select markets counterbalanced by softer growth in others 32% 66 0% ▪ Americas: Sales declined across territories; mainly USD million organic growth due to lower patient volumes than u
Slide 7: EBITDA margin expanding by 1%-points to 18% vs Q1 2024
EBITDA margin expanding by 1%-points to 18% vs Q1 2024. Expansion driven by higher Gross Profit margin and cost control in SG&A Gross Profit and Gross Profit margin Highlights USD million ▪ Gross Profit: Gross profit margin was 63% in Q1’25 vs. 62% (before special items) 63% in Q1’25 2023. The incre
Slide 8: Q1 Cash flow and leverage
Q1 Cash flow and leverage Capital expenditures and % of sales Free cash flow and % of sales Net Interest-Bearing Debt and Leverage USD million USD million USD million 482 470 460 33 34 437 11 414 11 3.3x 9 3.1x 8 18 2.9x 15% 15% 2.8x 2.6x 6 2.5x 8% 2.3x 2.4x 8 4% 5.7% 1.9x 5.0% 1.9x 4.1% 3.6% 3.0% -
Slide 9: 2025 Guidance
2025 Guidance Proposed Guidance as of Guidance as of Q1 2025 Feb 5 2025 April 29 2025 Sales growth 5-8% 4% 5-8% Organic EBITDA margin Before special 20-21% 18% 20-21% items For modeling purposes: Special items None None None In USD million CAPEX 3-4% 3% 3-4% % of sales Tax 23-24% 23% 23-24% Effectiv
Slide 10: Q&A: Key message from Q1 2025
Q&A Key message from Q1 2025 1. We are off to a good start to the year; driven by a strong finish to the quarter. Growth was strong in our Prosthetics & Neuro Orthotics segment supported solid growth in EMEA and APAC 2. André Rocha appointed as EVP of R&D and Conal Harte appointed EVP of Patient Car
Slide 11: Contact our Investor Relations
Contact our Investor Relations Financial calendar and events April 29 2025 Interim report Q1 2025 April 29 2025 Q1 2025 HCA Capital virtual presentation and Q&A April 30 2025 Q1 2025 Road Show Copenhagen (Carnegie) May 5 2025 Q1 2025 Road Show Frankfurt (Carnegie) May 6 2025 Q1 2025 Virtual Road Sho
Slide 12: EMBLA
@) EMBLA MEDICAL™